Mdm Hao Dongting (“Mdm Hao”) was appointed as a Non-Executive Director of the Company on 14 April 2021 and was re-designated as Non-Executive Chairperson of the Company on 25 May 2021. On 1 September 2023, Mdm Hao was subsequently re-designated as Executive Chairperson of the Company. Mdm Hao is responsible for providing leadership and direction to the Board of Directors of the Company, facilitating the operations, as well as focusing efforts on corporate strategy, strategic customer and partner relationships and corporate development.
Mdm Hao is also a director of OOWAY Technology Pte. Ltd., an associated company of the Group and a director of OOWAY Data Technology (Beijing) Co., Ltd. (大路数据科技(北京) 有限公司).
Mdm Hao holds a Master of Business Administration from the National University of Singapore. She attended a graduate programme in Economic Law at the Chinese Academy of Social Sciences and subsequently obtained a graduation certificate. Furthermore, Mdm Hao obtained a graduation certificate in Law from the Beijing Institute of Political Science and Law. In addition, Mdm Hao obtained a Certificate of Senior International Finance Manager from the International Financial Management Association.
Mr James Beeland Rogers, Jr. (“Mr Rogers”) was appointed as the Non-Executive and Non-Independent Director of the Company on 26 June 2023. Mr Rogers is a shareholder holding 8.55% interest in OOWAY Group Ltd., a controlling shareholder of the Company. Mr Rogers is also a co-founder and Chief Strategy Architect of OOWAY Technology Pte. Ltd. and its subsidiaries.
Mr Rogers is the author of several books and is a globally renowned financial commentator as well as a successful international investor. He is currently the Chairman of Beeland Interests, Inc. and he holds several companies’ directorships. In 1998, he started the Rogers International Commodity Index to track the value of commodities consumed in the global economy, ranging from agricultural to energy and metal products.
He obtained a Bachelor’s degree cum laude in History from Yale University in 1964 and a second Bachelor’s degree in Philosophy, Politics and Economics from Balliol College, Oxford University in 1966.
Ms Liu Ting ("Ms Liu") was appointed to the Group as CEO of Hainan Blue Code Biotechnology Co., Ltd on 8 October 2024, and redesignated as the Company’s CEO on 16 January 2026. She is responsible for the Group’s strategic direction, corporate development and planning as well as investor relations
A seasoned branding management expert, Ms. Liu has extensive experience in supply chain and operations management. She played a pivotal role in organising the initial entry of leading overseas biotechnology branding products into a well-known e-commerce platform in the Chinese market. Additionally, she has strong connections in the digital marketing sector. With nearly eight years of experience in internet digital marketing, she has conducted extensive research in e-commerce market operations and management, as well as five years of experience in the research and management of biotech anti-aging products.
Ms Liu also boasts nearly eight years of experience in the financial sector, focusing on market management in corporate banking.
Before joining the Group, Ms. Liu served as the Director and CEO of Beijing Peony Century Biotechnology Co., Ltd., where she was involved in product development, brand planning, and overall operational management. She also held the position of Vice President at Northern International Group's Factoring Company.
Ms Liu holds a degree in Financial Management from the University of Macau.
Mr Lam Kwong Fai (“Mr Lam”) was appointed as the Lead Independent Director of the Company on 26 June 2023. Mr Lam is engaged in the business of providing corporate finance advisory and compliance advisory in Singapore and the region. He started his career as a regulator before moving into investment banking handling a variety of initial public offerings (“IPOs”) and other corporate actions. He then moved into Catalist regulation, working with a wide portfolio of listed companies, advising on the listing rules and corporate governance. In his various corporate capacities, he has amassed almost 20 years of experience in the Singapore corporate finance and regulatory scene.
Mr Lam obtained a Bachelor of Accountancy from Nanyang Technological University in 2002. He is also an Independent Director of Soon Lian Holdings Limited, China Kunda Technology Holdings Limited, VCPlus Limited and Katrina Group Limited, all of which are listed on the SGX-ST.
Mr. Tan Thiam Hee ("Mr Tan") was appointed as an Independent Director of the Company on 18 May 2026.
Mr. Tan is a professionally trained accountant with over 20 years of experience as chief financial officer or chief executive officer in various industries, including marine, construction, property development and investments, pharmaceutical, leisure, manufacturing, trading and investments holding.
Mr. Tan is currently the Founder and Executive Director of Viva Corporate Advisory Pte Ltd, a business consulting company and the Acting Chief Executive Officer and Executive Director of Borden Company (Private) Limited, a manufacturer and distributor of Eagle brand products worldwide. He was previously the Group Chief Executive Officer and Executive Director of Emerging Towns & Cities Singapore Ltd., a company listed on the Catalist Board of SGX-ST and director of ACH Investments Pte Ltd, a corporate and financial advisory company in Singapore.
Mr. Tan holds a Master of Business Administration in International Business and a Bachelor of Accountancy (Merit) degree from the Nanyang Technological University, Singapore. He has an Executive Certificate in Corporate and Environmental Sustainability module 1 and 2 from Nanyang Business School, Nanyang Technological University, Singapore. Mr. Tan is a fellow member of the Institute of Singapore Chartered Accountants and CPA Australia, and a Senior Accredited Director of the Singapore Institute of Directors.
Mr Chueng Wai Man Raymond (“Mr Cheung”) was appointed as an Independent Director of the Company on 26 June 2023. Mr Cheung brings over 20 years of professional experience in actuarial, enterprise risk management (“ERM”), business consultancy, fund management, supply chain financing, financial technology as well as environmental, social, and governance (“ESG”) and sustainability. He joined Basel Medical Group as Director and Chief Executive Officer with effect from 1 July 2023. He is also the founder and Director of Alpha Millennia Technology providing digital transformation solutions to micro-, small- and medium-sized enterprises and communities in Indonesia. Mr Cheung is also a licensed Portfolio Manager managing multi-strategy sub-funds under the Variable Capital Companies structure. He was previously the Regional Insurance Lead at Grab where he pioneered digital insurance solutions for 8 ASEAN countries. Between 2011 and 2014, he was the Chief Risk Officer for a large insurance and a large reinsurance company in Singapore.
Mr Cheung is also an Independent Director of a Monetary Authority of Singapore licensed major payment institution, Atlantic Partners Asia (SG) Pte. Ltd., in Singapore. He is a professional ERM and ESG trainer in Asia who also conducts part-time lectures in several universities and institutions in Singapore.
Mr Cheung holds a Bachelor of Business (Actuarial Science major) from Nanyang Technological University. He is an associate member of the Institute & Faculty of Actuaries, United Kingdom and an associate member of the Singapore Actuarial Society.